| Title |
Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, September 2014
|
| DOI | 10.2147/tcrm.s47434 |
| Pubmed ID | |
| Authors |
Susanna Hilda Hutajulu, Johan Kurnianda, I Bing Tan, Jaap M Middeldorp |
| Abstract |
Nasopharyngeal carcinoma (NPC) is highly endemic in certain regions including the People's Republic of China and Southeast Asia. Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein-Barr virus (EBV) infection. The presence of EBV in all tumor cells, aberrant pattern of antibodies against EBV antigens in patient sera, and elevated viral DNA in patient circulation as well as nasopharyngeal site underline the role of EBV during NPC development. In NPC tumors, EBV expresses latency type II, where three EBV-encoded proteins, Epstein-Barr nuclear antigen 1, latent membrane protein 1 and 2 (LMP1, 2), are expressed along with BamH1-A rightward reading frame 1, Epstein-Barr virus-encoded small nuclear RNAs, and BamH1-A rightward transcripts. Among all encoded proteins, LMP1 plays a central role in the propagation of NPC. Standard treatment of NPC consists of radiotherapy with or without chemotherapy for early stage, concurrent chemoradiotherapy in locally advanced tumors, and palliative systemic chemotherapy in metastatic disease. However, this standard care has limitations, allowing recurrences and disease progression in a certain proportion of cases. Although the pathophysiological link and molecular process of EBV-induced oncogenesis are not fully understood, therapeutic approaches targeting the virus may increase the cure rate and add clinical benefit. The promising results of early phase clinical trials on EBV-specific immunotherapy, epigenetic therapy, and treatment with viral lytic induction offer new options for treating NPC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 66 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 18% |
| Researcher | 8 | 12% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Master | 7 | 10% |
| Student > Postgraduate | 5 | 7% |
| Other | 15 | 22% |
| Unknown | 13 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 30% |
| Biochemistry, Genetics and Molecular Biology | 8 | 12% |
| Agricultural and Biological Sciences | 7 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Nursing and Health Professions | 3 | 4% |
| Other | 11 | 16% |
| Unknown | 14 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 September 2014.
All research outputs
#22,759,452
of 25,374,647 outputs
Outputs from Therapeutics and Clinical Risk Management
#1,204
of 1,323 outputs
Outputs of similar age
#213,027
of 248,671 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#13
of 15 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,671 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.